Euro
British Pound
US Dollar
BMS-777607 |
|||
| 2455-5 | Biovision |
|
|
BMS-911543 |
|||
| 2630-1 | Biovision |
|
|
BMS-911543 |
|||
| 2630-5 | Biovision |
|
|
BMS-754807 |
|||
| 2631-1 | Biovision |
|
|
BMS-754807 |
|||
| 2631-5 | Biovision |
|
|
BMS-303141 |
|||
| 2821-10 | Biovision |
|
|
BMS-303141 |
|||
| 2821-50 | Biovision |
|
|
BMS-754807 |
|||
| A1185-100 | ApexBio | 100 mg |
|
|
Description: BMS-754807 is a potent and small molecular inhibitor which targets the IGF-1R/IR family kinases with Ki
|
|||
BMS-754807 |
|||
| A1185-25 | ApexBio | 25 mg |
|
|
Description: BMS-754807 is a potent and small molecular inhibitor which targets the IGF-1R/IR family kinases with Ki
|
|||
BMS-754807 |
|||
| A1185-5 | ApexBio | 5 mg |
|
|
Description: BMS-754807 is a potent and small molecular inhibitor which targets the IGF-1R/IR family kinases with Ki
|
|||
BMS-754807 |
|||
| A1185-5.1 | ApexBio | 10 mM (in 1mL DMSO) |
|
|
Description: BMS-754807 is a potent and small molecular inhibitor which targets the IGF-1R/IR family kinases with Ki
|
|||
BMS-599626 |
|||
| 1614-1 | Biovision |
|
|
BMS-599626 |
|||
| 1614-5 | Biovision |
|
|
BMS-378806 |
|||
| B1533-10 | ApexBio | 10 mg |
|
|
Description: BMS-378806 is a novel attachment inhibitor of HIV with EC50 values of 2.68±1.64nM, 26.5±3.5nM.
|
|||
BMS-378806 |
|||
| B1533-100 | ApexBio | 100 mg |
|
|
Description: BMS-378806 is a novel attachment inhibitor of HIV with EC50 values of 2.68±1.64nM, 26.5±3.5nM.
|
|||
BMS-378806 |
|||
| B1533-5 | ApexBio | 5 mg |
|
|
Description: BMS-378806 is a novel attachment inhibitor of HIV with EC50 values of 2.68±1.64nM, 26.5±3.5nM.
|
|||
BMS-378806 |
|||
| B1533-5.1 | ApexBio | 10 mM (in 1mL DMSO) |
|
|
Description: BMS-378806 is a novel attachment inhibitor of HIV with EC50 values of 2.68±1.64nM, 26.5±3.5nM.
|
|||
BMS-378806 |
|||
| B1533-50 | ApexBio | 50 mg |
|
|
Description: BMS-378806 is a novel attachment inhibitor of HIV with EC50 values of 2.68±1.64nM, 26.5±3.5nM.
|
|||
BMS-626529 |
|||
| B1557-25 | Biovision |
|
|
BMS-626529 |
|||
| B1557-5 | Biovision |
|
|
BMS-708163 |
|||
| B1622-25 | Biovision |
|
|
BMS-708163 |
|||
| B1622-5 | Biovision |
|
|
BMS-582949 |
|||
| B1704-1 | Biovision |
|
|
BMS-582949 |
|||
| B1704-5 | Biovision |
|
|
BMS-986205 |
|||
| B1839-25 | Biovision |
|
|
BMS-986205 |
|||
| B1839-5 | Biovision |
|
|
BMS-536924 |
|||
| B1908-1 | Biovision |
|
|
BMS-536924 |
|||
| B1908-5 | Biovision |
|
|
BMS-986158 |
|||
| B2021-1 | Biovision |
|
|
BMS-986158 |
|||
| B2021-5 | Biovision |
|
|
BMS-794833 |
|||
| B2055-5 | Biovision |
|
|
BMS-986020 |
|||
| B2290-25 | Biovision |
|
|
BMS-986020 |
|||
| B2290-5 | Biovision |
|
|
BMS-663068 |
|||
| B2299-25 | Biovision |
|
|
BMS-663068 |
|||
| B2299-5 | Biovision |
|
|
BMS-986142 |
|||
| B2420-1 | Biovision |
|
|
BMS-986142 |
|||
| B2420-5 | Biovision |
|
|
BMS 753 |
|||
| B5438-10 | ApexBio | 10 mg |
|
|
Description: Ki : 2 nM for RAR? Three retinoic acid receptors (RAR?, RAR? and RAR? and three retinoid X receptors, members of the nuclear receptor (NR) superfamily, mediate the biological effects of retinoic acids upon development, cell differentiation and proliferation, and homeostasis.
|
|||
BMS 753 |
|||
| B5438-50 | ApexBio | 50 mg |
|
|
Description: Ki : 2 nM for RAR? Three retinoic acid receptors (RAR?, RAR? and RAR? and three retinoid X receptors, members of the nuclear receptor (NR) superfamily, mediate the biological effects of retinoic acids upon development, cell differentiation and proliferation, and homeostasis.
|
|||
BMS-303141 |
|||
| B1079-10 | ApexBio | 10 mg |
|
|
Description: BMS-303141 is a potent inhibitor of ATP-citrate lyase with IC50 value of 0.13 ?M [1]. ATP-citrate lyase (ACL) is a cytosolic enzyme that responsible for the production of cytosolic acetyl-CoA, a precursor required for de novo biosyntheses of cholesterol and fatty acids.
|
|||
BMS-303141 |
|||
| B1079-25 | ApexBio | 25 mg |
|
|
Description: BMS-303141 is a potent inhibitor of ATP-citrate lyase with IC50 value of 0.13 ?M [1]. ATP-citrate lyase (ACL) is a cytosolic enzyme that responsible for the production of cytosolic acetyl-CoA, a precursor required for de novo biosyntheses of cholesterol and fatty acids.
|
|||
BMS-303141 |
|||
| B1079-5.1 | ApexBio | 10 mM (in 1mL DMSO) |
|
|
Description: BMS-303141 is a potent inhibitor of ATP-citrate lyase with IC50 value of 0.13 ?M [1]. ATP-citrate lyase (ACL) is a cytosolic enzyme that responsible for the production of cytosolic acetyl-CoA, a precursor required for de novo biosyntheses of cholesterol and fatty acids.
|
|||
BMS-303141 |
|||
| B1079-50 | ApexBio | 50 mg |
|
|
Description: BMS-303141 is a potent inhibitor of ATP-citrate lyase with IC50 value of 0.13 ?M [1]. ATP-citrate lyase (ACL) is a cytosolic enzyme that responsible for the production of cytosolic acetyl-CoA, a precursor required for de novo biosyntheses of cholesterol and fatty acids.
|
|||
BMS-794833 |
|||
| B1438-10 | ApexBio | 10 mg |
|
|
Description: BMS-794833 is a potent ATP competitive, dual inhibitor of c-Met and VEGFR2 (IC50 = 1.7 nM and 15 nM, respectively). It also has inhibitory effect on Ron, Axl and Flt3 (IC50 50% TGI for at least one tumor doubling time without significant toxicity in 14 days.
|
|||
BMS-794833 |
|||
| B1438-5 | ApexBio | 5 mg |
|
|
Description: BMS-794833 is a potent ATP competitive, dual inhibitor of c-Met and VEGFR2 (IC50 = 1.7 nM and 15 nM, respectively). It also has inhibitory effect on Ron, Axl and Flt3 (IC50 50% TGI for at least one tumor doubling time without significant toxicity in 14 days.
|
|||
BMS-794833 |
|||
| B1438-5.1 | ApexBio | 10 mM (in 1mL DMSO) |
|
|
Description: BMS-794833 is a potent ATP competitive, dual inhibitor of c-Met and VEGFR2 (IC50 = 1.7 nM and 15 nM, respectively). It also has inhibitory effect on Ron, Axl and Flt3 (IC50 50% TGI for at least one tumor doubling time without significant toxicity in 14 days.
|
|||
BMS-794833 |
|||
| B1438-50 | ApexBio | 50 mg |
|
|
Description: BMS-794833 is a potent ATP competitive, dual inhibitor of c-Met and VEGFR2 (IC50 = 1.7 nM and 15 nM, respectively). It also has inhibitory effect on Ron, Axl and Flt3 (IC50 50% TGI for at least one tumor doubling time without significant toxicity in 14 days.
|
|||
BMS-794833 |
|||
| B1438-S | ApexBio | Evaluation Sample |
|
|
Description: BMS-794833 is a potent ATP competitive, dual inhibitor of c-Met and VEGFR2 (IC50 = 1.7 nM and 15 nM, respectively). It also has inhibitory effect on Ron, Axl and Flt3 (IC50 50% TGI for at least one tumor doubling time without significant toxicity in 14 days.
|
|||
BMS-817378 |
|||
| B5862-10 | ApexBio | 10 mg |
|
|
Description: Description:IC50: 1.7 nM/15 nM for Met/VEGFR2 The signaling pathway of the receptor tyrosine kinase MET and its ligand hepatocyte growth factor is important for cell growth, survival, and motility.
|
|||
BMS-817378 |
|||
| B5862-5 | ApexBio | 5 mg |
|
|
Description: Description:IC50: 1.7 nM/15 nM for Met/VEGFR2 The signaling pathway of the receptor tyrosine kinase MET and its ligand hepatocyte growth factor is important for cell growth, survival, and motility.
|
|||
BMS-817378 |
|||
| B5862-50 | ApexBio | 50 mg |
|
|
Description: Description:IC50: 1.7 nM/15 nM for Met/VEGFR2 The signaling pathway of the receptor tyrosine kinase MET and its ligand hepatocyte growth factor is important for cell growth, survival, and motility.
|
|||
BMS-582949 |
|||
| B6187-1 | ApexBio | 1 mg |
|
|
Description: IC50: 13 nMBMS-582949 is a p38 MAPK inhibitorp38R MAP kinase plays a key role in regulating the biosynthesis of various inflammatory cytokines, such as tumor necrosis factor alpha and interleukin-1?.
|
|||
BMS-582949 |
|||
| B6187-25 | ApexBio | 25 mg |
|
|
Description: IC50: 13 nMBMS-582949 is a p38 MAPK inhibitorp38R MAP kinase plays a key role in regulating the biosynthesis of various inflammatory cytokines, such as tumor necrosis factor alpha and interleukin-1?.
|
|||
BMS-582949 |
|||
| B6187-5 | ApexBio | 5 mg |
|
|
Description: IC50: 13 nMBMS-582949 is a p38 MAPK inhibitorp38R MAP kinase plays a key role in regulating the biosynthesis of various inflammatory cytokines, such as tumor necrosis factor alpha and interleukin-1?.
|
|||
BMS-833923 |
|||
| 9547-25 | Biovision |
|
|
BMS-833923 |
|||
| 9547-5 | Biovision |
|
|
BMS-299897 |
|||
| 9606-25 | Biovision |
|
|
BMS-299897 |
|||
| 9606-5 | Biovision |
|
|
Bms 626529 |
|||
| 20-abx182383 | Abbexa |
|
|
|
|||
BMS 687453 |
|||
| C3544-10 | ApexBio | 10 mg |
|
|
Description: IC50: 10 nM for human PPAR?BMS 687453 is a PPAR? agonist.
|
|||
BMS 687453 |
|||
| C3544-25 | ApexBio | 25 mg |
|
|
Description: IC50: 10 nM for human PPAR?BMS 687453 is a PPAR? agonist.
|
|||
BMS 687453 |
|||
| C3544-5 | ApexBio | 5 mg |
|
|
Description: IC50: 10 nM for human PPAR?BMS 687453 is a PPAR? agonist.
|
|||
BMS 191011 |
|||
| B7146-10 | ApexBio | 10 mg |
|
|
Description: BMS 191011 is a maxi-K channel opener [1].Maxi-K channels consist of a pore-forming ? subunit and a regulatory ? subunit. Maxi-K channels are of a high Ca2+ sensitivity [2].Bath application of BMS-191011 at a concentration of 20 ?M strongly reduced the calcium transients.
|
|||
BMS 191011 |
|||
| B7146-25 | ApexBio | 25 mg |
|
|
Description: BMS 191011 is a maxi-K channel opener [1].Maxi-K channels consist of a pore-forming ? subunit and a regulatory ? subunit. Maxi-K channels are of a high Ca2+ sensitivity [2].Bath application of BMS-191011 at a concentration of 20 ?M strongly reduced the calcium transients.
|
|||
BMS 191011 |
|||
| B7146-5 | ApexBio | 5 mg |
|
|
Description: BMS 191011 is a maxi-K channel opener [1].Maxi-K channels consist of a pore-forming ? subunit and a regulatory ? subunit. Maxi-K channels are of a high Ca2+ sensitivity [2].Bath application of BMS-191011 at a concentration of 20 ?M strongly reduced the calcium transients.
|
|||
BMS 191011 |
|||
| B7146-50 | ApexBio | 50 mg |
|
|
Description: BMS 191011 is a maxi-K channel opener [1].Maxi-K channels consist of a pore-forming ? subunit and a regulatory ? subunit. Maxi-K channels are of a high Ca2+ sensitivity [2].Bath application of BMS-191011 at a concentration of 20 ?M strongly reduced the calcium transients.
|
|||
BMS 193885 |
|||
| B7327-10 | ApexBio | 10 mg |
|
|
Description: BMS-193885 is a potent and selective neuropeptide Y1 receptor antagonist with IC50 of 5.9nM.Neuropeptide Y receptor 1 is G-protein coupled receptors and implicated in the modulation of food intake and energy homeostasis.
|
|||
BMS 193885 |
|||
| B7327-50 | ApexBio | 50 mg |
|
|
Description: BMS-193885 is a potent and selective neuropeptide Y1 receptor antagonist with IC50 of 5.9nM.Neuropeptide Y receptor 1 is G-protein coupled receptors and implicated in the modulation of food intake and energy homeostasis.
|
|||
BMS 453 |
|||
| B7396-10 | ApexBio | 10 mg |
|
|
Description: BMS 453 is a synthetic RAR (retinoic acid receptor) antagonist [1]. The retinoic acid receptors (RAR?, RAR?, RAR?) belong to steroid nuclear receptor superfamily and the expressions of retinoid receptor RAR? and RAR? are correlated with the antiproliferative effects of retinoids.
|
|||
BMS 453 |
|||
| B7396-25 | ApexBio | 25 mg |
|
|
Description: BMS 453 is a synthetic RAR (retinoic acid receptor) antagonist [1]. The retinoic acid receptors (RAR?, RAR?, RAR?) belong to steroid nuclear receptor superfamily and the expressions of retinoid receptor RAR? and RAR? are correlated with the antiproliferative effects of retinoids.
|
|||
BMS 453 |
|||
| B7396-5 | ApexBio | 5 mg |
|
|
Description: BMS 453 is a synthetic RAR (retinoic acid receptor) antagonist [1]. The retinoic acid receptors (RAR?, RAR?, RAR?) belong to steroid nuclear receptor superfamily and the expressions of retinoid receptor RAR? and RAR? are correlated with the antiproliferative effects of retinoids.
|
|||
BMS 961 |
|||
| B7397-10 | ApexBio | 10 mg |
|
|
Description: BMS961 is a potent and selective retinoic acid receptor gamma (RAR?) agonist with IC50 values of 30 nM.RAR? belongs to the family of nuclear receptors which regulates transcription.
|
|||
BMS 961 |
|||
| B7397-50 | ApexBio | 50 mg |
|
|
Description: BMS961 is a potent and selective retinoic acid receptor gamma (RAR?) agonist with IC50 values of 30 nM.RAR? belongs to the family of nuclear receptors which regulates transcription.
|
|||
BMS 493 |
|||
| B7415-10 | ApexBio | 10 mg |
|
|
Description: BMS493 is an inverse agonist of pan-retinoic acid receptors (pan-RARs). This compound has been shown to increase nuclear corepressor (NCoR) interaction with RARs.
|
|||
BMS 493 |
|||
| B7415-25 | ApexBio | 25 mg |
|
|
Description: BMS493 is an inverse agonist of pan-retinoic acid receptors (pan-RARs). This compound has been shown to increase nuclear corepressor (NCoR) interaction with RARs.
|
|||
BMS 493 |
|||
| B7415-5 | ApexBio | 5 mg |
|
|
Description: BMS493 is an inverse agonist of pan-retinoic acid receptors (pan-RARs). This compound has been shown to increase nuclear corepressor (NCoR) interaction with RARs.
|
|||
BMS 195614 |
|||
| B7459-10 | ApexBio | 10 mg |
|
|
Description: BMS 195614 is a selective RAR? antagonist [1]. It can bind to the RAR? subunit [5].
|
|||
BMS 195614 |
|||
| B7459-5 | ApexBio | 5 mg |
|
|
Description: BMS 195614 is a selective RAR? antagonist [1]. It can bind to the RAR? subunit [5].
|
|||
BMS 195614 |
|||
| B7459-50 | ApexBio | 50 mg |
|
|
Description: BMS 195614 is a selective RAR? antagonist [1]. It can bind to the RAR? subunit [5].
|
|||
BMS 309403 |
|||
| B7794-10 | ApexBio | 10 mg |
|
|
Description: BMS309403 is specifically designed to target FABP4 with a Ki value less than 2 nM. It is a potent and selective FABP4 inhibitor.
|
|||
BMS 309403 |
|||
| B7794-25 | ApexBio | 25 mg |
|
|
Description: BMS309403 is specifically designed to target FABP4 with a Ki value less than 2 nM. It is a potent and selective FABP4 inhibitor.
|
|||
BMS 309403 |
|||
| B7794-5 | ApexBio | 5 mg |
|
|
Description: BMS309403 is specifically designed to target FABP4 with a Ki value less than 2 nM. It is a potent and selective FABP4 inhibitor.
|
|||
BMS 309403 |
|||
| B7794-5.1 | ApexBio | 10 mM (in 1mL DMSO) |
|
|
Description: BMS309403 is specifically designed to target FABP4 with a Ki value less than 2 nM. It is a potent and selective FABP4 inhibitor.
|
|||